
    
      This study is a prospective, randomized, open-label clinical trial. The study will be
      performed in patients after obtaining informed consent. Group assignment is by drawing a
      sealed envelops based on random table. (1) Group 1: Experimental group 30 cases, AclastaÂ®
      (Zoledronic acid 5mg/100ml) is given intravenously on the 4th postoperative day and one year
      after the total hip replacement, (2) Group 2: Control group, 30 cases, no bisphosphonate is
      given to the patients. Only the unilateral coxarthrosis will be recruited for the study.
      Patients will be analyzed with (1) DXA study (2) Clinical assessment (Harris hip score and
      SF-12) (3) X-ray (4) serum marker of bone turnover. Patients will be scheduled for specified
      examinations preoperatively, postoperatively 6 weeks, 3 months, 6 months, 12 months, and 24
      months.
    
  